SCHEDULE: Glazer Capital Reduces Stake in scPharmaceuticals Below 5%

Glazer Capital, LLC and Paul J. Glazer report a beneficial ownership of 4.64% in scPharmaceuticals Inc., indicating a reduction below the 5% threshold.

Summary

• Glazer Capital, LLC and Paul J. Glazer are the reporting persons for this Schedule 13G filing.
• They beneficially own 2,474,820 shares of scPharmaceuticals Inc. common stock, par value $0.0001 per share.
• This ownership represents 4.64% of the total class of securities.
• The reporting persons hold shared voting power and shared dispositive power over all 2,474,820 shares.
• As of the event date, the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership, not a performance report. The reduction in stake below 5% is a factual event without explicit positive or negative framing within the document itself.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Notifies the market of a reduction in a significant institutional investor's stake, which could be interpreted as a change in institutional confidence or a reallocation of capital, potentially influencing market sentiment and share price.

Key Dates

Keywords

scPharmaceuticals Inc., Glazer Capital, Paul J. Glazer, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Ownership